Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 March 2007Website:
http://www.palisadebio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:46:57 GMTDividend
Analysts recommendations
Institutional Ownership
PALI Latest News
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D.
– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics
Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET. As part of the event, J.D.
Palisade Bio stock is on the rise today following the release of more data for its ulcerative colitis treatment. The significant development is Palisade Bio finishing its evaluation of ex-vivo bioactivation of PALI-2108.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.
Biopharmaceutical company Palisade Bio (NASDAQ: PALI ) is seeing its market value skyrocket off multiple encouraging catalysts today. While PALI stock still remains an extremely risky proposition, investors are being buoyed by some key developments.
Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio is selling 2,339,398 shares of PALI stock through a registered direct offering.
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade said the license gives it exclusive worldwide rights to develop, make and commercialize Giiant's proprietary targeted prodrug platform which specializes in therapies for the IBS market.
What type of business is Palisade Bio?
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
What sector is Palisade Bio in?
Palisade Bio is in the Healthcare sector
What industry is Palisade Bio in?
Palisade Bio is in the Biotechnology industry
What country is Palisade Bio from?
Palisade Bio is headquartered in United States
When did Palisade Bio go public?
Palisade Bio initial public offering (IPO) was on 30 March 2007
What is Palisade Bio website?
https://www.palisadebio.com
Is Palisade Bio in the S&P 500?
No, Palisade Bio is not included in the S&P 500 index
Is Palisade Bio in the NASDAQ 100?
No, Palisade Bio is not included in the NASDAQ 100 index
Is Palisade Bio in the Dow Jones?
No, Palisade Bio is not included in the Dow Jones index
When does Palisade Bio report earnings?
Next earnings report date is not announced yet